The Joint Venture Blind Spot: What the Equity Line Doesn’t Tell You

• Reported JV investments can understate exposure from shareholder loans, guarantees, unfunded commitments, and other commercial arrangements (e.g., leases, take or pay offtake).
• Across 50 companies, the authors identify $612 billion in total JV exposure against $351 billion in reported investments.
• Analysts should assess the full obligations, potential cash calls, and partners’ ability to fund their share.

Joint ventures have become the load-bearing walls of the industrial economy.

In mining, over three-quarters of copper and nearly two-thirds of lithium production come from JVs; in oil and gas, roughly half the output at majors like Shell, ExxonMobil, and Chevron comes from ventures they do not operate.

Beyond natural resources, JVs now account for more than half of new AI-infrastructure partnerships and most new battery plants. Steep costs, a desire to spread the risk, and a decade of cheap money fueled the growth. New JV formation has risen nearly 550% since 2020.1

Higher rates have repriced the debt these structures run on, and the weakest partners are running out of room. The exposures built in the easy years now face their first real stress test.

Portfolio managers and equity and financial analysts, need to look beyond the reported “Investment in JV” line in company filings. That line tells the analyst very little - only the book value the company carries for the JV—and misses the venture’s overall economic exposure to the company.

A firm that moves a $10 billion investment into a JV reports lower leverage, a higher return on capital, and a leaner asset base — while a loan it makes to the venture counts as an asset, not debt.

The items that actually put capital at risk, shareholder loans, debt guarantees, and long-term purchase commitments, determine how much is on the line if the venture struggles.

We pulled the fiscal year 2025 filings of 50 of the world’s largest public companies across natural resources, energy, chemicals, automotive, semiconductors, and aerospace, and sought to rebuild five layers of JV exposure from the disclosures2:

1. Equity-method investment
2. Shareholder loans
3. Guarantees and contingent liabilities
4. Committed-but-unfunded capital
5. Take-or-pay arrangements3

Our analysis only includes equity-method JVs — the structures that collapse into a single balance-sheet line, where the blind spot lives. Every figure traces to a note. Where a company disclosed too little to quantify, we dropped it rather than guess, and we purposefully excluded joint operations, ventures a company controls and consolidates, and stakes too small to confer significant influence. The findings are deliberately a floor, not a ceiling.

The findings were eye-opening.

On paper, the 50 companies held $351 billion in JV investments. Their total implied exposure is at least $505 billion. The $154 billion difference is real loans and guarantees that no single balance-sheet line adds up. And that excludes capital committed but not yet paid. Add it, and the total reaches $612 billion (Exhibit 1).

Exhibit 1: Book Value vs. Total Economic Exposure – Aggregate 50 Companies (FY2025)

The total is the least interesting part. What matters is the gap between what a company reports and what it is actually carrying — the JV blind-spot multiplier.

For most of the cohort it is modest; for a handful, alarming. Take four examples.

1. TotalEnergies reports $30.7 billion of equity-method investments — plus $8.1 billion of loans to those JVs and $27.7 billion of guarantees on their borrowings, a real exposure of $66 billion, more than double the book figure and the largest in the group. None of the extra $35 billion is hidden; it is disclosed, just buried in notes few readers reach.
2. Meta is cleaner, precisely because JVs are not its story: its equity-method investments are about $7.5 billion, yet its Hyperion data center JV alone carries a roughly $28 billion residual-value guarantee — part of roughly $46 billion in total disclosed exposure, nearly twenty times the $2 billion at which that stake is carried, in an easily missed footnote.4
3. Then there is Dow, the stake is underwater: its investment in a petrochemical JV sits at negative book value after mounting losses, yet Dow still guarantees roughly $1.3 billion of the JV’s debt and believes “it is no longer remote” it will have to perform. The equity line calls the venture a write-off; the guarantee puts Dow on the hook for more than a billion dollars.
4. Volkswagen has $23 billion owed to by its JVs, almost twice what its stakes are worth. A shareholder loan is filed as an asset, but if the venture fails, the shareholder loan is paid last, if at all — the riskiest dollar a parent puts in, recorded as one of the safest.

“Investment in JV: $X” smooths these shapes into one number, yet a loan is first-loss money in an asset’s clothes, and a guarantee is a loan you have promised to take out the moment your partner cannot.

The fourth layer is the one the balance sheet skips entirely, and it looks forward, not back-capital these companies have signed up to fund but not yet paid in. Across the cohort, it adds $107 billion, the bridge between the $505 billion already at risk and the $612 billion of total exposure. These are not “maybes” but commitments already inked, likely to grow as project costs climb.

The fifth layer — long-term take-or-pay and offtake obligations — is the hardest to size from the notes and sits outside even the $612 billion, yet the rating agencies already treat it as debt-like, and so should an analyst.

Exhibit 2: Total JV Exposure – By Company5

Rating agencies and forensic accountants already see through this façade.

Moody’s Investors Service and S&P do not account for the equity-method line at face value; they haul a parent’s share of JV debt back onto the balance sheet, treat guarantees and offtake as debt-like, and rerun the leverage math on a look-through basis.

The same company holds two truths: the credit market sees one, the equity market often sees the other, and equity investors tend to learn what the bond desk already knew at the worst moment. That gap is also a screen: where reported and look-through leverage diverge most is where the next surprise sits.

In early 2015, an anonymous research firm laid bare the gap between a global commodity trader’s reported profits and the cash its business actually generated.

Noble Group was Asia’s largest commodity trader and a market favorite, running associates and JVs whose accounting did quiet lifting — booking fair-value gains on long-dated contracts to flatter profit while the cash flow said otherwise. One year it reported a profit while hemorrhaging more than a billion dollars in operating cash. Noble denied it, sued, and kept reporting. By the time the market came around, it had shed more than 90% of its value.

Disclosure rules don’t fix it. Companies must disclose these items, but only once they clear a materiality bar each sets for itself, and with wide latitude over how much to lump together. No rule says: hand the board one number for total economic exposure, JV by JV. Whether that number exists is a matter of the company’s own choices.

For any company with material JVs, analysts should:

1. Rebuild the five layers. Start with the equity-method line, then add shareholder loans, guarantees, committed-but-unfunded capital, and take-or-pay commitments. The ratio of that total to the equity line — the blind-spot multiplier — is the first screen. Almost no one adjusts for it, which is exactly why a JV flatters the reported numbers.
2. Recalculate on a look-through basis. Pull attributable JV debt, guarantees, and committed capital back into the parent’s figures, then re-run leverage and return on capital. On that basis, a JV-heavy company often looks very different from its reported ratios - and from its peers.
3. Expand the yardstick. The size of the equity stake is the wrong measure of how much can go wrong, so don’t let it decide how hard you look. Dig into any JV whose guarantees, shareholder loans, or annual offtake cross, say, 15% to 20% of the parent’s operating cash flow— regardless of how small the equity line is—along with any venture exposed to serious regulatory or reputational risk. A venture can be immaterial on the balance sheet and still be the thing that sinks the parent.
4. Test the partners. A partner whose balance sheet is mostly investments in associates, not assets it controls, may not fund the call when it matters most.

Half a trillion dollars across 50 companies is not hidden from the market. The rating agencies found it. The forensic accountants found it.

The exposure is simply too rarely assembled into a single number — and the analyst who builds it sees what the market has not yet priced.

^{The views expressed herein are those of the author(s) and not necessarily the views of Ankura Consulting Group, LLC, its management, its subsidiaries, its affiliates, or its other professionals. Ankura is not a law firm and cannot provide legal advice.}